Cargando…

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model

Detalles Bibliográficos
Autores principales:	Lyon, Amanda, Fallon, Jonathan, Boyerinas, Benjamin, Schmitz, Robert, Hance, Kenneth W, Lan, Yan, Sabzevari, Helen, Tsang, Kwong, Schlom, Jeffrey, Greiner, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288381/ http://dx.doi.org/10.1186/2051-1426-2-S3-P101

Ejemplares similares

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
por: Fallon, Jonathan K., et al.
Publicado: (2017)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
por: Morillon, Y. Maurice, et al.
Publicado: (2019)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
por: Knudson, Karin M., et al.
Publicado: (2018)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Tumor Establishment Features of Orthotopic Murine Bladder Cancer Models
por: Lee, Jin Seok, et al.
Publicado: (2012)

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
por: Yi, Ruibin, et al.
Publicado: (2022)

Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
por: Lim, Soyeon, et al.
Publicado: (2023)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Tumor and Microenvironment Modification during Progression of Murine Orthotopic Bladder Cancer
por: Tham, Sin Mun, et al.
Publicado: (2011)

A New Method of Establishing Orthotopic Bladder Transplantable Tumor in Mice
por: Yang, Xi-hua, et al.
Publicado: (2012)

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
por: Ozawa, Yohei, et al.
Publicado: (2021)

Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model
por: Lu, Yuan, et al.
Publicado: (2021)

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
por: Knudson, Karin M., et al.
Publicado: (2019)

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts
por: Vallo, Stefan, et al.
Publicado: (2016)

Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice
por: Westwood, Jennifer A., et al.
Publicado: (2014)

Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer
por: Hahn, Ho-Suap, et al.
Publicado: (2014)

Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model
por: Watanabe, Fábio T., et al.
Publicado: (2011)

Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model
por: Mori, Jun‐ich, et al.
Publicado: (2021)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors
por: Gmeiner, William H., et al.
Publicado: (2013)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts
por: Coutinho de Souza, Patricia, et al.
Publicado: (2015)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
por: Li, Xiaolei, et al.
Publicado: (2021)

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
por: Minnar, Christine M, et al.
Publicado: (2022)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2021)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer
por: Tse, Brian W.-C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e8ap4muq6pcj2u6fj6q3p6ebqu